Form 4: Day One Biopharma COO/CFO Reports RSU Vesting, Tax-Related Stock Sale

Day One Biopharmaceuticals' COO and CFO, Charles N. York II, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax liabilities.

Summary

• Charles N. York II, COO and CFO, reported transactions involving Day One Biopharmaceuticals, Inc. common stock.
• On November 15, 2025, a total of 16,875 Restricted Stock Units (RSUs) vested and converted into common stock (1,375 + 2,250 + 6,625 + 6,625 shares).
• Following these acquisitions, Mr. York's direct beneficial ownership of common stock increased to 298,777 shares.
• On November 17, 2025, Mr. York sold 4,062 shares of common stock at a weighted average price of $8.9147 per share.
• The sale was explicitly stated to be for the sole purpose of covering tax liability associated with the RSU settlement.
• After the sale, Mr. York's direct beneficial ownership of common stock stands at 294,715 shares.
• The reported beneficial ownership also includes 3,902 shares acquired through the Issuer's employee stock purchase plan between May 12, 2023, and November 14, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The vesting of RSUs is a positive sign of continued executive compensation and service. The subsequent sale of shares is for tax purposes, which is a neutral event and not indicative of a lack of confidence in the company. The overall beneficial ownership remains high.

Positives

• Vesting of 16,875 Restricted Stock Units (RSUs) indicates continued service and compensation for the COO and CFO.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating pre-planned, non-discretionary trades.
• The reporting person's beneficial ownership remains substantial at 294,715 shares after the transactions.

Negatives

• A sale of 4,062 shares occurred, reducing the direct beneficial ownership.

Future Outlook

The filing indicates future RSU vesting will occur quarterly on February 15, May 15, August 15, and November 15, contingent on the reporting person's continued service to the Issuer.

Stakeholder Impact

• Shareholders: The sale of shares for tax purposes is a routine event and does not signal a change in management's confidence. The continued vesting of RSUs indicates ongoing executive commitment.
• Employees: The mention of an employee stock purchase plan (ESPP) indicates a benefit available to employees.

Next Steps

• Future RSU vesting will occur quarterly on February 15, May 15, August 15, and November 15, subject to the reporting person's continued service.

Key Dates

Recommendation

The Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of Restricted Stock Units and a subsequent sale of shares solely to cover tax obligations. These actions are pre-planned under a Rule 10b5-1(c) plan and do not reflect a discretionary decision by the COO and CFO to reduce their stake due to concerns about the company's performance or outlook. The executive maintains a substantial beneficial ownership. Therefore, this filing alone does not provide new information that would warrant a change in investment recommendation; a 'hold' stance is appropriate as it reflects the absence of significant positive or negative discretionary signals.

Keywords

Day One Biopharmaceuticals, DAWN, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Sale, Tax Liability, Charles N. York II, COO, CFO, Biotechnology, Pharmaceuticals